What is the clinical evidence from this study?

Study design: Observational. Population: Pulmonary fibrosis. Intervention: Pulmonary fibrosis vs. Healthy/non-fibrotic controls. Primary outcome: Serum levels of neoepitope-specific biomarkers reflecting type III, IV, and VI collagen production and degradation (p=PRO-C3: p=0.0006, all others: p<0.0001).

What question did this study set out to answer?

To determine whether circulating neoepitope biomarkers of type III, IV, and VI collagen remodeling originate directly from lung tissue in patients with pulmonary fibrosis.

August 20, 2026Scientific ReportsOpen Access

Circulating biomarkers reflecting type III, IV and VI collagen remodeling are present in lung tissue of patients with pulmonary fibrosis and non-fibrotic controls

Q: What are the key findings of this study?

Collagen remodeling biomarkers were significantly increased in the serum of patients with pulmonary fibrosis compared with healthy controls (PRO-C3: p=0.0006, all others: p<0.0001).

Q: What question did this study set out to answer?

To determine whether circulating neoepitope biomarkers of type III, IV, and VI collagen remodeling originate directly from lung tissue in patients with pulmonary fibrosis.

View Full Paper

Ask AI

Bookmark

Key result

Pulmonary fibrosis is linked to elevated serum collagen remodeling biomarkers versus healthy controls.

P RO-C3: p=0.0006, all others: p<0.0001

Why the study?

It was unknown whether systemic neoepitope-specific collagen remodeling biomarkers associated with pulmonary fibrosis originate directly from human lung tissue.

Are circulating neoepitope-specific collagen remodeling biomarkers present in and released from human lung tissue in patients with pulmonary fibrosis compared to controls?

Population

21 patients with pulmonary fibrosis and 21 non-fibrotic or healthy controls

Comparison

Patients with pulmonary fibrosis vs controls

Design

Case-control study

Authors

HBHelene W. BreisnesUniversity of Copenhagen SKSissel Brix Kronborg-WhiteAarhus University FSFilipa B. SimõesNordic Bioscience (Denmark)

Discussion

Member takes

Implication

Supports potential diagnostic utility of collagen biomarkers in pulmonary fibrosis; leaves open their prognostic value and clinical adoption pending prospective validation.

Key Points

To determine whether circulating neoepitope biomarkers of type III, IV, and VI collagen remodeling originate directly from lung tissue in patients with pulmonary fibrosis.
Analyzed lung tissue samples from patients with pulmonary fibrosis (n = 21) and non-fibrotic controls (n = 21) using formal-fixed paraffin-embedded and snap-frozen preparations.
Quantified collagen production (PRO-C3, PRO-C4, PRO-C6) and degradation (C3M, C4M, C4Ma3, C6M) biomarkers in serum from patients with pulmonary fibrosis and healthy controls (n = 21).
Evaluated biomarker release from proteolytically cleaved lung tissue (pepsin, collagenase, MMP-9) and mapped their spatial distribution using immunohistochemistry.
All serum collagen remodeling biomarkers were significantly elevated in patients with pulmonary fibrosis compared to healthy controls (PRO-C3: p = 0.0006; PRO-C4, PRO-C6, C3M, C4M, C4Ma3, C6M: p < 0.0001).
Degradation neoepitopes (C3M, C4M, and C6M) were generated and released from both non-fibrotic and fibrotic lung tissue following proteolytic enzyme cleavage.
Immunohistochemistry demonstrated widespread distribution of type III and IV collagen fragments across lung tissue, whereas type VI collagen formation (PRO-C6) showed a compartment-specific pattern.

Study Design

Type

Observational

Structured PICO

Are circulating neoepitope-specific collagen remodeling biomarkers present in and released from human lung tissue in patients with pulmonary fibrosis compared to controls?

Population

Patients with pulmonary fibrosis and non-fibrotic/healthy controls evaluated for collagen remodeling biomarkers in lung tissue and serum.

Exposure

Measurement of neoepitope-specific biomarkers reflecting type III, IV, and VI collagen production (PRO-C3, PRO-C4, and PRO-C6) and degradation (C3M, C4M, C4Ma3, and C6M)

Comparator

Non-fibrotic/healthy controls

Outcome

Serum levels and lung tissue presence/spatial distribution of collagen remodeling biomarkerssurrogate

Main Result

p-value: PRO-C3: p=0.0006, all others: p<0.0001

Neoepitope-specific collagen remodeling biomarkers are elevated in the serum of patients with pulmonary fibrosis and can be directly traced to generation and release from human lung tissue.

Cite This Study

Breisnes et al. (2026) conducted an observational in Pulmonary fibrosis. Pulmonary fibrosis vs. Healthy/non-fibrotic controls was evaluated on Serum levels of neoepitope-specific biomarkers reflecting type III, IV, and VI collagen production and degradation (p=PRO-C3: p=0.0006, all others: p<0.0001). Collagen remodeling biomarkers were significantly increased in the serum of patients with pulmonary fibrosis compared with healthy controls (PRO-C3: p=0.0006, all others: p<0.0001).

synapsesocial.com/papers/6a86b4cb8a91293e6a1cc4a8 https://doi.org/10.1038/s41598-026-66831-4

View Full Paper

Ask AI

Bookmark

Implication

Supports potential diagnostic utility of collagen biomarkers in pulmonary fibrosis; leaves open their prognostic value and clinical adoption pending prospective validation.

Circulating biomarkers reflecting type III, IV and VI collagen remodeling are present in lung tissue of patients with pulmonary fibrosis and non-fibrotic controls

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Circulating biomarkers reflecting type III, IV and VI collagen remodeling are present in lung tissue of patients with pulmonary fibrosis and non-fibrotic controls

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider